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Abstract
Background: Both (-) and (+)-naloxone attenuate inflammation-mediated neurodegeneration by inhibition of
microglial activation through superoxide reduction in an opioid receptor-independent manner. Multiple lines of
evidence have documented a pivotal role of overactivated NADPH oxidase (NOX2) in inflammation-mediated
neurodegeneration. We hypothesized that NOX2 might be a novel action site of naloxone to mediate its anti-
inflammatory actions.
Methods: Inhibition of NOX-2-derived superoxide by (-) and (+)-naloxone was measured in lipopolysaccharide
(LPS)-treated midbrain neuron-glia cultures and phorbol myristate acetate (PMA)-stimulated neutrophil membranes
by measuring the superoxide dismutase (SOD)-inhibitable reduction of tetrazolium salt (WST-1) or ferricytochrome
c. Further, various ligand (
3H-naloxone) binding assays were performed in wild type and gp91
phox-/- neutrophils and
transfected COS-7 and HEK293 cells. The translocation of cytosolic subunit p47
phox to plasma membrane was
assessed by western blot.
Results: Both (-) and (+)-naloxone equally inhibited LPS- and PMA-induced superoxide production with an IC50 of
1.96 and 2.52 μM, respectively. Competitive binding of
3H-naloxone with cold (-) and (+)-naloxone in microglia
showed equal potency with an IC50 of 2.73 and 1.57 μM, respectively.
3H-Naloxone binding was elevated in COS-7
and HEK293 cells transfected with gp91
phox; in contrast, reduced
3H-naloxone binding was found in neutrophils
deficient in gp91
phox or in the presence of a NOX2 inhibitor. The specificity and an increase in binding capacity of
3H-naloxone were further demonstrated by 1) an immunoprecipitation study using gp91
phox antibody, and 2)
activation of NOX2 by PMA. Finally, western blot studies showed that naloxone suppressed translocation of the
cytosolic subunit p47
phox to the membrane, leading to NOX2 inactivation.
Conclusions: Strong evidence is provided indicating that NOX2 is a non-opioid novel binding site for naloxone,
which is critical in mediating its inhibitory effect on microglia overactivation and superoxide production.
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Recent studies strongly support that neuroinflammation
plays a critical role in the pathogenesis of various neuro-
degenerative diseases, including Alzheimer’s disease
(AD), Parkinson’s disease (PD), amyotrophic lateral
sclerosis (ALS), multiple sclerosis, Huntington’s disease
and multiple system atrophy [1]. Microglia, the resident
immune cells of the brain, are the major players in the
initiation of neuroinflammation and subsequent patho-
genesis of neurodegeneration. Once activated, microglia
produce and release a variety of proinflammatory factors,
such as cytokines, chemokines and reactive free radicals,
which contribute to the neurodegenerative process [2].
Thus, anti-inflammatory therapy has been considered a
new strategy for disease-modifying intervention.
I nt h ec o u r s eo fd e v e l o p i n g new anti-inflammatory
drugs for PD, we discovered that naloxone, a commonly
used antagonist of opioid receptors, was highly effective
in preventing dopaminergic neurodegeneration in differ-
ent rodent PD models by inhibiting inflammatory
responses [3-6]. The inhibitory effects of naloxone on
inflammatory responses have been reported in our pre-
vious studies in vivo and in vitro. Systemic infusion of 1
mg/kg (+)- or (-)-naloxone significantly reduced intrani-
gral LPS-induced microglial activation and neurotoxicity
[5]. In midbrain and cortical neuron-glia cultures,
microglial activation and related proinflammatory cyto-
kine production such as nitrite oxide, TNFa and IL-1b,
in response to LPS stimulation, were also attenuated by
naloxone at 0.1-1 micromolar concentrations [3,4].
Further dose-response study showed a bimodal curve
(effective in both micromolar and subpicomolar, but
less effective in nanomolar concentrations) for both
anti-inflammatory and neuroprotective effects of nalox-
one [7]. Despite a huge concentration difference,
mechanistic studies have revealed that inhibition of
microglial superoxide production is the key event
underlying naloxone-afforded neuroprotection for both
micromolar and subpicomolar concentrations [3,6,7].
Furthermore, we have reported that the neuroprotective
effect of naloxone is independent of opioid receptors,
since (+)-naloxone, which is an inactive isomer in the
activation of opioid receptors, exerts the same potency
as the (-)-naloxone in neuroprotection [3-6]. Recent
reports from several laboratories have also shown opioid
receptor-independent actions of naloxone. Watkins’
group reported that (+)-naltrexone, (+)-naloxone and
(-)-naloxone, which they showed to be Toll-like recep-
tor 4 (TLR4) antagonists in vitro on both stably trans-
fected HEK293-TLR4 and microglial cell lines, suppress
neuropathic pain with complete reversal upon chronic
infusion [8,9]. In a drug addiction study, Wang et al.
demonstrated that the acute Gs coupling induced by
morphine is completely prevented by co-treatment with
both (-) and (+)-naloxone [10]. Similarly, it has been
reported that naloxone displays neuroprotective effects
in a two-hit seizure model by reducing both cytokine
production and microglial activation [11]. Both (-) and
(+)-naloxone have also been found to be capable of
reducing the severity of aortic atherosclerosis in apoli-
poprotein-E (apo-E)-deficient mice through inhibition of
macrophage activation and superoxide release [12].
Taken together, the non-opioid actions of naloxone may
have wide implications in therapy for a variety of dis-
eases. Thus, it is critical to elucidate the novel non-
opioid binding site(s) and action mechanisms of
naloxone.
The major purpose of this study was to search for the
potential site of action mediating the anti-inflammatory
and neuroprotective effects of naloxone using a ligand
(
3H-naloxone) binding assay. We have initially
attempted to determine both the low (micromloar) and
high (subpicomolar) affinity sites of naloxone. However,
t h es p e c i f i ca c t i v i t yo f
3H-naloxone is too low to study
the binding at subpicomolar concentrations. Thus, the
main effort of this study focused on the micromolar
concentrations of naloxone. Here, for the first time, we
report that gp91
phox, the catalytic subunit of microglial
NOX2, is a novel non-opioid binding site of naloxone.
Binding of naloxone reduced the translocation of cyto-
solic subunits to the plasma membrane, leading to inhi-
bition of NOX2 and related superoxide production,
which is critical in mediating the anti-inflammatory and
neuroprotective effects of naloxone.
Methods
Reagents
[
3H]-naloxone was purchased from Perkin Elmer Life
Sciences (Boston, MA, USA). Cell culture reagents were
obtained from Invitrogen Life Technologies (Grand
I s l a n d ,N Y ,U S A ) .R a b b i ta n t i - p 4 7
phox was purchased
from Upstate (Billerica, MA, USA). FITC-conjugated
goat anti-rabbit immunoglobulin G (IgG) was obtained
from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). Rabbit anti-b-actin was obtained from
S i g m a( S t .L o u i s ,M O ,U S A ) .M o u s ea n t i - g p 9 1
phox was
purchased from BD Transduction Laboratories (San
Jose, CA, USA).
Animals
NOX2-deficient (gp91
phox-/-) and wild type (WT)
C57BL/6 J (gp91
phox+/+) mice were obtained from the
Jackson Laboratory. All animals were housed in a patho-
gen free facility with a 12-hour light/12-hour dark cycle
and ad libitum access to food and water. Housing,
breeding and experimental use of the animals were per-
formed in strict accordance with the National Institutes
of Health guidelines.
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Briefly, dissociated cells were seeded at 1 × 10
5/well in
poly-D-lysine coated 96-well plates. The cultures were
maintained at 37°C in a humidified atmosphere of 5%
CO2 and 95% air in minimum essential medium (MEM)
containing 10% heat-inactivated fetal bovine serum
(FBS), 10% heat-inactivated horse serum, 1 g/L glucose,
2 mM L-glutamine, 1 mM sodium pyruvate, 100 μM
nonessential amino acids, 50 U/ml penicillin, and 50 μg/
ml streptomycin. Seven days later, cultures were used
for drug treatments. At the time of treatment, immuno-
cytochemical analysis indicated that the neuron-glia cul-
ture consisted of 10% microglia, 50% astrocytes, 40%
neurons, and 1% tyrosine hydroxylase (TH)-immunor-
eactive neurons. For treatment, cultures were changed
to treatment medium composed of MEM, 2% FBS, 2%
HHS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50
U/ml penicillin, and 50 μg/ml streptomycin.
Superoxide assay
The production of superoxide was assessed by measur-
ing the superoxide dismutase (SOD) -inhibitable reduc-
tion of the tetrazolium salt WST-1. Primary neuron/glia
cultures in 96-well plates were washed twice with
Hanks’ balanced salt solution (HBSS) without phenol
red. Cells were then incubated at 37°C for 30 minutes
with vehicle control or (-) and (+)-naloxone in HBSS
(50 μl/well). Subsequently, 50 μl of HBSS with and with-
out SOD (50 U/ml) was added to each well along with
50 μlo fW S T - 1( 1m M )i nH B S Sa n d5 0μl of vehicle
or LPS. The absorbance at 450 nm was read with a
SpectraMax Plus microplate spectrophotometer (Mole-
cular Devices) every 2 minutes for 30 minutes. The dif-
ference between the absorbances in the presence and
absence of SOD was considered to be the amount of
produced superoxide.
Preparation, activation, and fractionation of rat blood
neutrophils and cell-free assay of NADPH-dependent
superoxide production by PMA-stimulated neutrophils
membranes.
Neutrophils were purified from fresh blood collected
from the abdominal aorta of adult Fischer 344 male rats
as described before [13]. Briefly, heparinized blood was
sedimented with dextran, and the neutrophils were iso-
lated by centrifugation through the Ficoll-Hypaque den-
sity gradient, followed by a hypotonic lysis to remove
residual erythrocytes. Purified neutrophils (> 95% viable
cells, trypan blue exclusion) were resuspended in
warmed phenol red-free HBSS (37°C) and stimulated for
15 minutes with 100 nM PMA or vehicle with gentle
agitation. The reaction was stopped by the addition of
ice-cold HBSS buffer. Pelleted cells were disrupted and
fractionated at 4°C by discontinuous sucrose density
gradient sedimentation as described before. Superoxide
generation in membrane fractions was measured by
monitoring the reduction of ferricytochrome c in a spec-
trophotometer with the water-jacketed cuvette compart-
ment maintained at 37°C. The reaction was initiated by
the addition of 0.2 mM (final concentration) freshly pre-
pared NADPH (tetrasodium salt, Type I, Sigma) into
1.0-ml micro-cuvettes containing detection buffer (100
μM ferricytochrome c, 10 μMF A D ,2m MM g C l 2,2m
NaNs, and 10 mM Hepes, pH 7.4) and 10 μgo fm e m -
brane. (-) or (+)-Naloxone (a final concentration of 10
μM) or vehicle was added quickly to micro-cuvettes to
determine the inhibition of superoxide production. The
reference cuvette was supplemented with 600 U/ml
SOD (Type I, 3000 U/mg protein, Sigma). Initial rates of
superoxide production were calculated from the linear
segment of the increase in absorbance at 550 nm and
normalized to vehicle-treated control.
Xanthine/xanthine oxidase reaction
To determine whether naloxone acts as a superoxide
scavenger, the superoxide-generating xanthine/xanthine
oxidase system was used. Briefly, assays were performed
in the presence of indicated concentrations of (-) and
(+)-naloxone isomers, 0.01 U xanthine oxidase, 50 μM
xanthine, 250 μM partially acetylated WST-1 in 50 mM
potassium phosphate buffer (pH 7.6) in a 96-well plate
(100 μL/well final volume). Xanthine was added to initi-
ate the reaction, and absorbance at 450 nm was con-
tinuously monitored for 5 minutes using a Synergy HT
multi-detection microplate reader (Bio-Tek Instruments,
Winooski, VT, USA). Results are expressed as a percen-
tage of the increase in absorbance per minute observed
with xanthine oxidase only.
Plasmid transfection
HEK293 cells were maintained in DMEM supplemented
with 10% fetal bovine serum at 37°C in a humidified
atmosphere of 5% CO2 and 95% air. One day before
transfection, 1 × 10
6 HEK293 cells were seeded into 6-
well plates. Flag-gp91
phox and Myc/His-p22
phox plasmids
were cotransfected into HEK293 cells using Lipofecta-
mine 2000 (Invitrogen Life Technologies, Grand Island,
NY) according to the manufacture’sp r o t o c o l .A f t e r4 8
hours of expression, cells were collected for binding
experiments.
Isolation of neutrophils from peritoneal cavity
Inflammation was induced by injecting 1 ml of casein
solution into the peritoneal cavity of gp91
phox-/- and
gp91
phox+/+ mice for overnight and repeat injection the
next morning. Three hours after the second injection,
mice were euthanized and 5 ml harvest solution (0.02%
EDTA in PBS) was injected into the peritoneal cavity.
All peritoneal fluids were transferred into 50 ml
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minutes. The pellets were washed three times using
PBS, and then collected for use [14].
[
3H]-naloxone binding assay
Binding experiments were performed according to the
methods of Herren, Liu and Zhou [4,15,16]. Briefly,
whole cell (2 × 10
6 or 4 × 10
6) or membrane (250 μg)
from neutrophils, COS-7, HEK293 or BV2 microglia
were incubated with [
3H]-naloxone (6 nM) plus 10 μM
unlabeled naloxone isomers in binding buffer (HBSS +
10% serum) for 2 hours at 4°C. Afterward, the buffer
was removed and cells or membrane were washed three
times with ice-cold HBSS using 1.0 μm pore size glass
fiber filter (Whatman, Florham Park, NJ, USA). Then,
cells or membranes were mixed with 10 ml of Ultima
Gold scintillation fluid (PerkinElmer, Waltham, MA,
USA) and counted for radioactivity. Experiments were
performed in triplicate and results are expressed as per-
centage of total binding observed with corresponding
WT group.
[
3H]-naloxone immunoprecipitation binding
The
3H-naloxone immunoprecipitation binding study
was performed by immunoprecipitation using anti-
gp91
phox antibody (IP-binding). Specifically, we prepared
plasma membranes from wild type COS-7 and COS-7-
gp91
phox-p22
phox (COS-7 cells stably expressed with
gp91
phox and p22
phox). Membrane pellets were sus-
pended in 0.5 ml IP buffer (10 mM HEPES (pH 7.4), 1%
Triton X-100, 5 mM Mg2Cl, 10 mM KCl, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 1 mM dithiothreitol
(DTT), 10% glycerin and protease inhibitor cocktails).
After pre-incubation with
3H-labeled naloxone (6 nM)
i nt h ep r e s e n c eo f1 0μM unlabeled naloxone for 30
minutes, membrane aliquots (0.25 mg protein) were
incubated overnight with the addition of control immu-
noglobulin G (IgG) or anti-gp91
phox polyclonal antibody
(Santa Cruz Biotech, Santa Cruz, CA) at 4°C. Immuno-
precipitation was performed by protein A/G beads
(Santa Cruz Biotech). After 4 hours incubation at 4°C,
protein beads were washed three times by IP buffer.
Then the beads were eluted twice by 0.5 ml glycine buf-
fer (0.1 M at pH 2.5), and radioactivity was counted
with a liquid scintillation counter. The binding capacity
was determined by subtracting the binding of control
IgG from that of gp91
phox antibody.
Membrane fractionation and western blot analysis
Membrane fractionations were extracted as described
previously [17]. BV2 microglia were lysed in hypotonic
lysis buffer (1 mM Tris, 1 mM KCl, 1 mM ethylene gly-
col tetraacetic acid (EGTA), 1 mM ethylenediaminete-
traacetic acid (EDTA), 0.1 mM DTT, 1 mM PMSF, and
10 μg/ml) cocktail protease inhibitor incubated on ice
for 30 minutes and then subjected to Dounce homoge-
nization (20-25 St, tight pestle A). The lysates were cen-
trifuged at 1,600 × g for 15 minutes and the supernatant
was centrifuged at 100,000 × g for 30 minutes. The pel-
lets solubilized in 1% Nonidet P-40 hypotonic lysis buf-
fer were used as membranous fraction. Equal amounts
of protein were separated by 4% to 12% Bis-Tris Nu-
PAGE gel and transferred to polyvinylidene difluoride
membranes (Bio-Rad, Hercules, CA, USA). Membranes
were blocked with 5% nonfat milk and incubated with
rabbit anti-p47
phox and mouse anti-gp91
phox (1/1,000
dilution) and HRP-linked anti-rabbit or mouse IgG (1/
3000 dilution) for 2 hours. Enhanced chemilumines-
cence (ECL) reagents (Amersham Biosciences, Piscat-
away, NJ, USA) were used as a detection system.
Statistical analysis
The data were presented as the mean ± SE. For multiple
comparisons of groups, analysis of variance (ANOVA)
was used. Statistical significance between groups was
assessed by paired or unpaired Student’s t test, with
Bonferroni’s correction. A value of P <0 . 0 5w a s
considered.
Results
Naloxone inhibits superoxide production through
inhibition of NOX2
Although naloxone has been reported to inhibit super-
oxide production, the detailed mechanism is not known.
In the present study, we first demonstrated that super-
oxide production induced by LPS was significantly
i n h i b i t e db y( - )a n d( + ) - n a l o x o n ei s o m e r si nad o s e -
dependent manner with a half maximal inhibitory con-
centration (IC50) of 1.96 and 2.52 μM, respectively (Fig-
ure 1A). These values are much higher than the IC50
for the binding of opioid receptors (in nanomolar), but
they are in similar ranges to those previously reported
for inhibiting superoxide production in neutrophils [18].
These results also support the contention that naloxone
inhibition of superoxide is independent of opioid recep-
tors. Our previous reports indicate that naloxone in
these micromolar concentrations was not toxic to cell
cultures and no obvious toxic signs were observed in
animal studies with a 10 mg/kg/day dosage [3-6]. To
rule out the possibility that the reduction of LPS-
induced superoxide release was attributed to the super-
oxide scavenging capacity of naloxone, we evaluated the
effect of various concentrations of (-) and (+)-naloxone
on superoxide production using the xanthine/xanthine
oxidase superoxide-generating system. The increased
l e v e lo fs u p e r o x i d eb yt h ex a n t h i n e / x a n t h i n eo x i d a s e
system was largely inhibited in the presence of SOD
(Figure 1), but not by both (-) and (+)-naloxone (0.01 to
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ited LPS-induced increase of superoxide from microglia
was not due to the superoxide scavenging capacity.
Since NOX2 is a major superoxide-generating enzyme
in activated immune cells including microglia [19], we
then examined whether naloxone directly targeted
NOX2 and suppressed superoxide production in a cell-
free system. Since it is difficult to generate a sufficient
amount of cell membrane from primary microglia for
this assay, we used blood neutrophils, which contain a
high abundance of NOX2. Neutrophils were first treated
w i t hP M A ,aw i d e l yu s e da g e n tf o rs u p e r o x i d ep r o d u c -
tion by stimulating NOX2; and then cell membranes
were isolated and used for the measurement of superox-
i d ep r o d u c t i o nb ya d d i n gN A D P H ,f e r r i c y t o c h r o m ec ,
a n dF A D .A ss h o w ni nF i g u r e1 C ,b o t h( - )a n d
(+)-naloxone (10 μM) inhibited NADPH-dependent
superoxide generation by PMA-stimulated neutrophil
membranes. This result indicates a direct inhibitory
effect of naloxone on NOX2.
3H-Naloxone binding is increased in the presence of the
gp91
phox membrane subunit
The gp91
phox is the catalytic subunit of NOX2 enzyme
and mainly locates in the plasma membrane of neutro-
phils, microglia and macrophages. We hypothesized that
Figure 1 Naloxone inhibits superoxide production through inhibition of NOX2. A. (-) and (+)-Naloxone isomers are equipotent in inhibiting
LPS-induced superoxide production. Neuron/glia cultures were pretreated with (-) or (+)-naloxone for 30 minutes before the addition of LPS (15
ng/ml), the production of superoxide was immediately assessed after LPS challenge by measuring SOD-inhibitable reduction of the WST-1. B.
Both (-) and (+)-naloxone lack superoxide scavenging capacity. Briefly (-) or (+)-naloxone, xanthine oxidase (10 mU), and WST-1 (250 μM) were
mixed in potassium phosphate buffer (PBS, 50 mM, pH 7.6). Xanthine (50 μM, final concentration) was added to initiate the reaction (final
volume, 1 ml). Absorbance at 450 nm was continuously monitored. C. (-) and (+)-Naloxone (10 μM) inhibited NADPH-dependent superoxide
production by PMA-stimulated neutrophil membranes in a cell-free system, as measured by the reduction of ferricytochrome c. Results are
expressed as a percentage of the control and are mean ± SEM of three independent experiments performed in duplicate. SOD was used as a
control to demonstrate its effectiveness to remove superoxide from the system. **P < 0.01 compared with corresponding control group. NOX2,
NADPH oxidase; SOD, superoxide dismutase; WST-1, water soluble tetrazolium salt 1; PMA, phorbol myristate acetate.
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superoxide production by directly binding to the
gp91
phox. To test this possibility, ligand binding assays
were performed using various cell types containing or
lacking the gp91
phox. Initially, BV2 cells, a murine
microglia cell line, were used for competition studies.
Binding of
3H labeled (-)-naloxone was displaced with a
wide range of both cold (-) and (+)-naloxone (0.01 μM
to 100 μM). As shown in Figure 2, both (-) and
(+)-naloxone inhibited
3H-naloxone binding to BV2
microglia in a dose-dependent manner with an IC50 of
2.73 and 1.57 μM, respectively. These IC50 values for
binding affinity are similar to the IC50 values for inhi-
biting LPS-induced superoxide production (Figure 1A:
1.92 and 2.56 μM), indicating a well-correlated event
between the binding and the inhibition of NOX2. Since
the binding affinity of (-)-naloxone toward opioid recep-
tors is approximately 10,000 times higher than that of
(+)-naloxone, the equi-potency of these two naloxone
isomers in binding to BV2 microglia represents a novel
opioid receptor-independent binding site.
To investigate whether naloxone could bind to the
gp91
phox subunit, we performed binding experiments by
using neutrophils, which contain the highest level of
gp91
phox among phagocytes, prepared from gp91
phox-/-
and gp91
phox+/+ (WT) mice. Whole cells or cell
membrane fractions (cell free system) prepared from
neutrophils were incubated with
3H-naloxone for 2 hour
at 4°C. The binding capacity of naloxone to the gp91
phox
in WT neutrophils was determined by comparing it with
that of gp91
phox-/- neutrophils. Deficiency in gp91
phox sig-
nificantly decreased naloxone binding to neutrophils in
both whole cell and cell membranes (Figure 3A). Similar
experiments were performed using COS-7 cells stably
expressed with the gp91
phox and p22
phox (COS-7-
gp91
phox-p22
phox) or in combination with p47
phox and
p67
phox (COS-NOX2) (Detailed transfection results are
shown in Figure 4). The reason for the co-transfection of
gp91
phox and p22
phox is that p22
phox facilitates stable
expression of gp91
phox in the plasma membrane of COS7
cells [20]. As shown in Figure 3B,
3H-naloxone binding
capacity was much higher in gp91
phox-transfected cells
compared with empty vector-transfected COS-7 cells,
which do not express gp91
phox. Transient expression of
gp91
phox in HEK293 cells was also found to elevate nalox-
one binding (Figure 3B). It should be noted that the
decrease of naloxone binding in gp91
phox deficiency neu-
trophils was about 40% of total binding, the remaining
50% to 60% was attributed to nonspecific binding. This
result is consistent with a previous report by Simpkins et
al. showing about 60% nonspecific
3H-naloxone binding
in human neutrophils [18]. The presence of opioid recep-
tors in phagocytes [21] and the low binding affinity of
3H-naloxone to the gp91
phox subunit may explain the
relatively high non-specific binding in ours and Simpkins’
r e p o r t .T oi n s u r et h es p e c i f i c i t yo fn a l o x o n eb i n d i n gt o
gp91
phox, we have further performed an immunoprecipi-
tation study using anti-gp91
phox antibody. A much higher
increase (2.5 fold) in the binding of
3H-naloxone to
immunoprecipitated COS7-gp91
phox-p22
phox membrane
proteins was observed compared with immunoprecipi-
tated COS-7 WT membrane proteins with no gp91
phox
(Figure 3C). Together, these binding results imply that
naloxone could directly interact with the gp91
phox-
p22
phox complex, and specially, subunit gp91
phox.
NOX2 activation by PMA enhances the binding capacity
of naloxone
The above-described naloxone binding studies were per-
formed while NOX2 was in the resting stage. Additional
experiments were performed to determine the binding
capacity of naloxone while the enzyme was in the acti-
vated stage. For this purpose, PMA, a widely used com-
pound for the activation of NOX2, was used. It is known
that through the activation of PKC, PMA induces the
translocation of the cytosolic subunits to the membrane
and increases the production of superoxide in phago-
cytes. In the present study, we examined the binding
capacity of naloxone to gp91
phox after PMA treatment in
COS-7-NOX2 cells. PMA treatment activated NOX2 by
Figure 2 Displacement of
3H-naloxone by both (-) and
(+)-naloxone in BV2 microglia. BV2 microglia (2 × 10
6) were used
for binding experiments. Cells were incubated with hot and
indicated fold concentrations of cold naloxone in binding buffer
(HBSS + 10% serum) for 2 hours at 4°C. Afterward, the medium was
removed and cells or membrane were washed seven times with
ice-cold HBSS. Cells were lysed with 400 μl of 1 N NaOH. Cell lysate
or membrane was mixed with 10 ml of Ultima Gold scintillation
fluid and counted for radioactivity. Results are expressed as
percentage of total binding observed with hot naloxone alone and
are mean ± SEM of three independent experiments performed in
duplicate. **P < 0.01 compared with the corresponding control
group,
##P < 0.01 compared with SOD group. HBSS, hank’s buffered
salt solution.
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nits (Figure 5). As shown in Figure 6, naloxone binding
was elevated in PMA-treated COS-7-NOX2 cells com-
pared to the vehicle treatment. PMA treatment had no
influence on background binding of naloxone to COS-7
cells. These results suggest that changes in the conforma-
tion resulted from the binding of cytosolic subunits to
the gp91
phox, rendering NOX2 in the activated stage, may
enhance the binding of naloxone.
Diphenyliodonium (DPI), a NOX2 inhibitor, reduces
3H-
naloxone binding
It was reported that DPI binds to the redox core, such
as photoreduced flavin or heme of the gp91
phox,a n d
subsequently prevents electron transport [22,23]. Our
results showed that DPI pretreatment reduced the bind-
ing of naloxone in WT neutrophils and the capacity of
naloxone binding became the same between WT con-
trols and the gp91
phox-/- group (Figure 7A). DPI failed to
attenuate
3H-naloxone binding to gp91
phox-/- neutro-
phils. Similar results were also demonstrated in COS-7
cells stably expressed with the gp91
phox-p22
phox complex
with or without the cytosolic subunits. The increases in
3H-naloxone binding in transfected cells were not
observed in DPI-treated groups (Figure 7B). These data
suggest a possible competition between naloxone and
DPI. However, it is important to note that it is not clear
from this study whether naloxone and DPI compete for
Figure 3 3H-naloxone binding is increased in the presence of the gp91
phox. A. Neutrophils (WT and gp91
phox-/-) whole cell and cell
membrane, B. COS-7 (WT: transfected with empty vector; gp91
phox-p22
phox: transfected with gp91
phox-p22
phox subunit and NOX2: transfected
with gp91
phox-p22
phox and cytosolic subunits) and HEK293 (WT and gp91
phox-p22
phox transfected with gp91
phox-p22
phox, detailed transfection
results are shown in Figure 4) were incubated with
3H-naloxone (6 nM) in binding buffer (HBSS + 10% serum) for 2 hours at 4°C. Afterward, the
buffer was removed and cells or membrane were washed seven times with ice-cold HBSS. C. Plasma membranes isolated from COS7 and COS7-
gp91
phox-p22
phox were used to perform the radiolabeled binding directly or to conduct IP using anti-gp91
phox antibody and the radio-labeled
binding assay (IP-binding assay). Then, cell or membrane was mixed with 10 ml of Ultima Gold scintillation fluid and counted for radioactivity.
Results are expressed as a percentage of the control and are mean ± SEM of three independent experiments performed in duplicate. **P < 0.01
compared with corresponding WT group. IP, immunoprecipitation; HBSS, hank’s buffered salt solution.
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DPI have different binding sites on gp91
phox. Conforma-
tional changes of gp91
phox after DPI binding may reduce
naloxone’s binding to gp91
phox. It remains to be deter-
mined whether naloxone binds to heme, the C-terminal
flavin domain, or any specific domain of gp91
phox.
Pre-treatment of naloxone inhibits translocation of the
NOX2 p47
phox cytosolic subunit to membrane
NOX2 consists of the membrane catalytic subunits
gp91
phox and p22
phox, together with several cytosolic reg-
ulatory subunits, p47
phox,p 4 0
phox,p 6 7
phox and a small
GTPase RAC [24]. It has previously been shown that
activation of the NOX2 enzyme requires that the cyto-
solic component p47
phox be phosphorylated and subse-
quently translocated along with the p67
phox component
to the plasma membrane, where they associate with the
gp91
phox component to assemble into an active enzyme
complex. To determine how naloxone inhibited NOX2
activity after binding to the gp91
phox, we investigated the
membrane translocation of p47
phox by determining the
cytosolic and membrane levels of p47
phox. BV2 microglia
were pretreated with vehicle or naloxone for 30 minutes,
followed by LPS treatment for 15 minutes. Western blot
analyses showed an increase in p47
phox levels in the
membrane fraction of BV2 microglia 10 minutes after
LPS exposure, which was prevented by naloxone pre-
treatment (Figure 8). At the same time, the decrease of
p47
phox levels in the cytosolic fraction of BV2 microglia
induced by LPS was also attenuated by naloxone.
Together, these results suggest that binding of naloxone
to the gp91
phox may change the conformation of this
membrane component, preventing the membrane trans-
location of cytosolic subunits of NOX2.
Post-treatment of naloxone is still capable of inhibiting
pre-existing increased binding of p47
phox in membrane
elicited by pre-treatment of LPS
Results from the previous figure (Figure 8) indicate that
pre-treatment with naloxone inhibits LPS-induced
superoxide and that this is associated with reduction of
translocation of cytosolic subunits to the plasma mem-
brane. It is interesting to note that our previous report
indicated that post-treatment with naloxone is also par-
tially effective in preventing LPS-induced DA neuron
Figure 4 Gp91
phox-p22
phox complex is expressed in COS-7 and
HEK293 cells. A. Western-blot analysis for gp91
phox, p22
phox, p47
phox
and p67
phox in COS-7-gp91
phox-p22
phox and COS-7-NOX2 cells. B.
Western-blot analysis for gp91
phox and p22
phox in HEK293 cells.
Briefly, 1 × 10
6 HEK293 cells were seeded into 6-well plates. Flag-
gp91
phox and Myc/His-p22
phox expression plasmids were co-
transfected into HEK293 cells using Lipofectamine 2000 according
the commercial protocol. After 48 hours of expression, cells were
collected for western-blot detection.
Figure 5 PMA induces p47
phox and p67
phox translocation to the
membrane in COS-7-NOX2 cells. COS-7-NOX2 cells were
pretreated with the indicated concentrations of PMA for 20 minutes.
Membrane fractions were isolated to perform western blot analysis.
Results are expressed as a percentage of the control and are mean
± SEM of three independent experiments performed in duplicate.
**P < 0.01 compared with the corresponding control group. PMA,
phorbol myristate acetate.
Figure 6 NOX2 activation by PMA enhances the binding
capacity of naloxone. COS-7-NOX2 (stably expression of NOX2
enzyme) cells were pretreated with the indicated concentrations of
PMA for 20 minutes. Then cells were used for binding experiments.
After incubation with
3H-naloxone for 2 hours at 4°C, cells were
mixed with 10 ml of Ultima Gold scintillation fluid and counted for
radioactivity. The binding data were normalized by protein
concentrations. Experiments were performed in triplicate and results
are expressed as percentage of total binding observed with WT
COS-7 alone. **P < 0.01 compared with corresponding WT group;
#P
< 0.05 and
##P < 0.01 compared with and without the PMA
treatment group, respectively. PMA, phorbol myristate acetate.
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enon, we hypothesize that naloxone is also capable of
attenuating NOX2 activity by reducing the amount of
membrane-bound p47 and other cytosolic subunits pro-
duced by LPS. For this purpose, an experiment using a
post-treatment of naloxone paradigm was conducted by
preparing membrane fractions from BV2 microglia,
which were pre-treated with LPS or vehicle for 15 min-
utes, and then incubated with or without naloxone. As
shown in Figure 9, pre-treatment of LPS activated
NOX2 enzyme by inducing translocation to the mem-
brane of the cytosolic subunit p47
phox. After 30 minutes
of naloxone post-treatment, the levels of p47
phox in the
membrane significantly decreased, which suggests nalox-
one counteracted the membrane translocation of the
cytosolic subunit p47
phox. These results suggest that
naloxone can inhibit the activated NOX2 enzyme by
reducing the binding of cytosolic subunits to the
membrane.
Discussion
In this study, we demonstrate a non-opioid novel nalox-
one binding site, which is critical in mediating its anti-
inflammatory actions. The salient features of our find-
ings are: 1) both (-) and (+)-naloxone inhibit LPS- and
PMA-induced superoxide production in neuron-glia cul-
tures and neutrophil membranes, respectively. In con-
trast, both isomers failed to reduce superoxide produced
by the xanthine/xanthine oxidase system, indicating that
the inhibition of superoxide production by naloxone is
Figure 8 Pre-treatment with naloxone inhibits translocation of
the NOX2 p47
phox cytosolic subunit to membrane. BV2 microglia
were pretreated with vehicle or naloxone for 30 minutes, followed
by LPS treatment for 15 minutes. Membrane and cytosolic fractions
were isolated to perform western blot analysis using p47
phox and
gp91
phox antibodies. Results are expressed as a percentage of the
control and are mean ± SEM of three independent experiments
performed in duplicate. **P < 0.01 and
##P < 0.01 compared with
corresponding WT and LPS treatment group, respectively; LPS,
lipopolysaccharide.
Figure 7 Diphenyliodonium (DPI), a NOX2 inhibitor, reduces
3H-naloxone binding. A. Neutrophil (WT and gp91
phox-/-)a n dB.C O S - 7( W T :
transfected with empty vector, gp91
phox-p22
phox: transfect with gp91
phox-p22
phox subunit and NOX2: transfected with gp91
phox-p22
phox and
cytosolic subunits, detailed transfection results are shown in Figure 4) were incubated with
3H-naloxone (6 nM) and DPI in binding buffer (HBSS
+ 10% serum) for 2 hour at 4°C. Afterward, the buffer was removed and cells or membrane were washed seven times with ice-cold HBSS. Then,
cells or membranes were mixed with 10 ml of Ultima Gold scintillation fluid and counted for radioactivity. Results are expressed as a percentage
of the control and are mean ± SEM of three independent experiments performed in duplicate. **P < 0.01 compared with corresponding control
group,
## P < 0.01 compared with NO DPI group.
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2) specific binding of
3H-naloxone to gp91
phox,t h e
membrane subunit of NOX2, was demonstrated by an
immunoprecipitation study using gp91
phox antibody, and
the binding affinity was further enhanced after NOX2
was activated; 3) Pre-treatment with naloxone prevented
the translocation of cytosolic subunits of NOX2 to the
plasma membrane. In addition, post-treatment with
naloxone of activated NOX2 reduced the binding of
cytosolic subunits with plasma membrane. Taken
together, this study provides strong evidence demon-
strating that naloxone directly binds to gp91
phox.
Decreased NOX2-generated superoxide production was
critical in mediating the anti-inflammatory and neuro-
protective effects of naloxone (Figure 10).
Several reports have documented that naloxone inhi-
bits superoxide production from microglia and neutro-
phils in an opioid receptor-independent manner
[6,18,26]; however, the underlying mechanism remains
unclear. Since naloxone contains a phenolic hydroxyl
group, we first assessed the possibility that the reduction
in superoxide production is due to its free radical
scavenging effect. This possibility was ruled out since
both (-)- and (+)-naloxone failed to reduce levels of
superoxide produced by the xanthine/xanthine oxidase
system (Figure 1). This finding led us to propose the
possibility that naloxone acts by interfering with
upstream events of superoxide generation. Using differ-
ent types of phagocytes deficient in the gp91
phox subunit
or non-phagocytes transfected with different subunits of
NOX2, we provide clear evidence indicating a direct
binding of naloxone to the membrane subunit, gp91
phox
(Figure 3).
3H-Naloxone binding capacity was decreased
in neutrophils deficient in gp91
phox. In contrast,
3H-
naloxone binding in COS-7 and HEK293 cells trans-
fected with gp91
phox was elevated compared with vehi-
cle-transfected controls. After enrichment of gp91
phox
protein from COS-7-gp91
phox-p22
phox cell membranes
by immunoprecipitation using anti-gp91
phox antibody,
the radiolabeled naloxone binding showed greater differ-
ences in the presence and absence of gp91
phox (Figure
3C). Overall, our data show a good correlation between
the binding affinity of naloxone to the gp91
phox and its
inhibition of LPS-induced superoxide production with
similar IC50 values (around 2 μM, Figures 1A &2).
It is important to note that the micromolar IC50
values reported here are much higher than the reported
binding affinity of
3H-naloxone to conventional opioid
receptors (in nanomolar concentrations) [27]. The ques-
tion is whether these concentrations are clinically rele-
vant for the anti-inflammatory and neuroprotective
effects of naloxone. Earlier reports indicated that micro-
molar concentrations can be reached both in serum and
brains after naloxone treatment. Tepperman et al.
showed that the peak plasma naloxone concentrations
in rats were 2.1 and 17 μMa f t e ras i n g l es u b c u t a n e o u s
injection of naloxone with doses of 1.0 or 10 mg/kg,
respectively. Furthermore, it has been reported that
brain levels of naloxone are six to seven times higher
than that in plasma [28], which might be attributed to
involvement of a pH-dependent and saturable influx
transport system in the blood-brain barrier transport of
naloxone [29]. Our previous report showed that sys-
temic infusion of naloxone (0.4 to 4 mg/kg/day for two
weeks with a mini-osmotic pump) dose-dependently
attenuated LPS-induced nigral dopaminergic neuron
loss in rats [5], and this further supports this contention.
Although we have identified microglial gp91
phox as a
novel binding site in mediating the anti-inflammatory
effect of naloxone, the underlying mechanism of how
the binding affects subsequent NOX2 activation remains
to be studied. Several studies have reported that nalox-
one could directly alter membrane characteristics. In a
Figure 9 Post-treatment with naloxone is still capable of
inhibiting pre-existing increased binding of p47
phox in
membrane elicited by pre-treatment of LPS. BV2 microglia were
pretreated with vehicle or LPS for 15 minutes. Membrane fractions
were isolated and incubated with vehicle or naloxone for 30
minutes at 37°C. Then, the reaction mixture was centrifuged at
100,000 × g for 30 minutes. The pellet was isolated to perform
western blot analysis using p47
phox and gp91
phox antibodies,
gp91
phox as an internal membrane control. Results are expressed as
a percentage of the control and are mean ± SEM of three
independent experiments performed in duplicate. **P < 0.01 and
##P < 0.01 compared with corresponding WT and LPS treatment
group, respectively. LPS, lipopolysaccharide.
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demonstrated that naloxone increases circulating lysoso-
mal hydrolase activities and suggested that this action
results from stabilization of lysosomal membranes [30].
Similarly, inhibition of Na
+ and K
+ currents in myeli-
nated nerve fibers of sciatic nerve and membrane poten-
tial of some cells have also been reported [31,32]. Thus,
we speculated that binding of naloxone to gp91
phox
might change the conformation of the protein complex
and subsequently decrease the affinity of binding of the
cytosolic subunits (p47
phox,p 6 7
phox). One common
approach to determine the binding affinity between the
cytosolic and membrane subunits of NOX2 is the mea-
surement of translocation of cytosolic subunits to the
membrane. Since it is known that the p67
phox is the sub-
unit that directly binds to the gp91
phox protein, it would
be desirable to measure the translocation of this subunit.
However, the lack of suitable antibodies against p67
phox
prevented us from performing this experiment. For this
reason, an antibody against p47
phox, which is also bound
to the membrane through formation of a complex with
p67
phox, was used.
Our speculation is supported by the finding that
naloxone pre-treatment reduces the translocation of
p47
phox (Figure 8). It is of interest to note that post-
treatment with naloxone was also capable of reducing
the LPS-induced increase in the amount of phosphory-
latd p47
phox in the cell membrane fraction (Figure 9).
These results suggest that binding of naloxone to acti-
vated NOX2 may alter the conformation of gp91
phox
and subsequently decrease binding affinity between
cytosolic subunits and the membrane subunit. Although
we do not yet have evidence showing actual conforma-
tional change of gp91
phox after naloxone binding, this
Figure 10 Summary of the potential mechanism of NOX2 inhibition by naloxone. Naloxone (Nal) inhibits activation of NOX2 and
superoxide production by directly binding to the gp91
phox-p22
phox complex, and then preventing the translocation of cytosolic subunits. It is
interesting to note that the binding capacity of
3H-naloxone to the gp91
phox-p22
phox complex was greatly enhanced after activation of NOX2.
Binding of naloxone to the gp91
phox-p22
phox complex may change the conformation of the protein complex and subsequently decrease the
affinity of binding of the cytosolic subunits (p47
phox, p67
phox).
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one is still effective in anti-inflammation and neuropro-
tection. That conformational changes can also alter the
binding capacity of
3H-naloxone binding is further illu-
strated by the finding that binding of
3H-naloxone in
NOX2-transfected COS-7 cells was greatly enhanced
after NOX2 was activated by PMA (Figure 6). Taken
together, our data strongly suggest that naloxone alters
binding affinity between gp91
phox and the cytosolic
subunits.
The non-opioid actions of naloxone have recently
received wide attention mainly due to its potential new
indications for a variety of diseases. One of the major
advances in this research area is the recognition of an
anti-nociceptive action of naloxone. Glial activation has
been demonstrated to oppose opioid analgesia and
enhance opioid tolerance, dependence, reward and
respiratory depression by upregulating the production of
proinflammatory cytokines (TNFa,I L - 1 ) ,p a i n - r e l e v a n t
neurotransmitters from sensory afferent terminals and
t h en u m b e ra n d / o rc o n d u c t i v i t yo fA M P Aa n dN M D A
glutamate receptors [33-35]. Naloxone, including both
(-) and (+) isomers, has been reported to potentiate
morphine analgesia equally by blocking morphine-
induced glial activation and consequent increases in
anti-analgesic proinflammatory cytokines [8,9,36]. Simi-
larly, hyperalgesia induced by morphine-3-glucoronide
(M3G), a major morphine metabolite that has little or
no affinity for opioid receptors, is also blocked or
reversed by (-) and (+)-naloxone [37]. TLR4 was
recently recognized to mediate such effects [38-40].
Experiments are underway in our laboratory to deter-
mine whether the anti-inflammatory effect of naloxone
mentioned above is due to a direct action on the TLR-4
receptor or is indirect through the inhibition of NOX2
inhibition. We performed a radioligand binding assay
with microglia prepared from TLR-4-deficient mice. Pre-
liminary results failed to show a decrease in
3H-nalox-
one binding in TLR-4-deficient microglia compared
with wild type controls (Wang et al., preliminary obser-
vations). Thus, the inhibitory effect shown on the TLR-4
receptor is likely due to an indirect effect through bind-
i n gt oN O X 2 .I nf a c t ,w eh a v ep r e v i o u s l yr e p o r t e dt h a t
naloxone inhibits LPS-induced production of proinflam-
matory factors, such as TNFa and prostaglandins,
through inhibition of NOX2-generated superoxide
release [41]. Regardless of the site of action, the poten-
tial interactions between TLR-4 and NOX2 can be a cri-
tical pathway governing innate immunity and warrant
further study.
Naloxone belongs to a class of compounds termed as
morphinans, with chemical structures similar to mor-
phine. We have previously reported that a large number
of morphinan analogs, such as (-) and (+) morphine
[42], dextromethorphan [43,44], 3-hydroxymorphinan
[45,46] and sinomenine [47] display potent anti-inflam-
matory and neuroprotective effects similar to that of
naloxone. These morphinan analogs have recently
received a great deal of attention due to their new thera-
peutic implications for a variety of diseases, ranging
from neuroprotection, anti-nociception, and bipolar
depression to drug addiction. Using both in vivo and
primary neuron-glia cell cultures derived from
gp91
phox-/- mice, we have previously reported that
NOX2 is critical in mediating this morphinans-afforded
neuroprotection similar to that of naloxone. Further,
our preliminary data show that dextromethorphan is
able to bind similarly to what we describe for naloxone
in this paper, suggesting that gp91
phox might be a com-
mon binding site for the above-mentioned morphinans
in their anti-inflammatory property (unpublished data).
Conclusions
In summary, we provided strong evidence indicating
that NOX2 is a non-opioid novel binding site for nalox-
one, which is critical in mediating its inhibitory effect
on microglia overactivation and superoxide production.
Although the new implications elicited by the mechan-
isms of morphinan analogs remain to be studied, the
identification of this novel non-opioid binding site med-
iating the important anti-inflammatory action of nalox-
one should provide new insights into further
understanding the mechanism of action of other mor-
phinan analogs and help better design new drugs target-
ing this important free radical-producing enzyme.
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